Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
21.51M | 18.34M | 17.16M | 35.92M | 26.69M | 17.58M | Gross Profit |
8.14M | 8.30M | 4.18M | 9.98M | 10.31M | 10.35M | EBIT |
440.00K | 161.00K | -804.00K | 3.88M | 1.39M | 2.29M | EBITDA |
1.72M | 2.22M | 1.45M | 6.29M | 3.98M | 5.19M | Net Income Common Stockholders |
-3.52M | -3.22M | -3.89M | -15.09M | -2.66M | -3.34M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
582.00K | 582.00K | 953.00K | 843.00K | 6.79M | 4.19M | Total Assets |
60.47M | 60.47M | 62.18M | 68.58M | 105.70M | 108.03M | Total Debt |
43.96M | 43.96M | 53.65M | 55.40M | 84.94M | 90.32M | Net Debt |
43.38M | 43.38M | 52.70M | 54.56M | 78.14M | 86.14M | Total Liabilities |
63.38M | 63.38M | 62.00M | 64.86M | 95.30M | 96.92M | Stockholders Equity |
-2.92M | -2.92M | 185.00K | 3.72M | 10.40M | 11.10M |
Cash Flow | Free Cash Flow | ||||
1.04M | 1.41M | 2.75M | -3.88M | 4.77M | 845.00K | Operating Cash Flow |
1.58M | 1.94M | 3.71M | -3.60M | 4.89M | 1.29M | Investing Cash Flow |
-540.00K | -530.00K | -958.00K | -281.00K | -123.00K | -450.00K | Financing Cash Flow |
-1.96M | -2.13M | -2.48M | -2.06M | -2.42M | -1.39M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
76 Outperform | $1.65B | 15.71 | 11.19% | 2.25% | 19.16% | 31.92% | |
69 Neutral | $1.03B | 38.80 | 11.28% | ― | 30.04% | 43.47% | |
56 Neutral | $1.58B | ― | -91.17% | ― | 3.88% | -34.30% | |
56 Neutral | $493.52M | ― | -70.23% | ― | 26.13% | 37.38% | |
52 Neutral | $5.19B | 3.04 | -44.20% | 2.82% | 16.59% | -0.39% | |
46 Neutral | $5.00M | ― | ― | 23.70% | -109.93% | ||
33 Underperform | $13.18M | ― | -951.52% | ― | -0.70% | -2.38% |
Regional Health Properties, Inc. is facing delisting proceedings from the NYSE American due to non-compliance with listing standards, as affirmed by the exchange’s Committee for Review. Despite this challenge, the company remains committed to its planned merger with SunLink Health Systems, although the approval of any securities issued in the merger by a national securities exchange is not guaranteed.
Spark’s Take on RHEP Stock
According to Spark, TipRanks’ AI Analyst, RHEP is a Neutral.
The overall score reflects significant financial challenges, including weak profitability and a highly leveraged balance sheet. While technical indicators show positive momentum, the poor valuation with a negative P/E ratio limits the stock’s attractiveness. Sustained improvements in financial performance are crucial for a positive outlook.
To see Spark’s full report on RHEP stock, click here.